Advertisement

Multitarget Fecal Immunochemical Test Ups Diagnostic Accuracy

0

Cross-validated sensitivity improved with multitarget FIT compared with standard FIT test for advanced neoplasia and advanced adenoma

Rates of Adverse Events Lower With Apixaban for A-Fib in Older Adults

0

Apixaban the only direct oral anticoagulant linked to lower adverse event rates than warfarin for patients with atrial fibrillation across frailty levels

Non-Antimicrobial Drugs Tied to Drug-Resistant Bacterial Infection

0

Proton pump inhibitors, beta-blockers, antimetabolites linked to infection with antibiotic-resistant bacteria

ASH Suggests Not Using Outpatient Thromboprophylaxis for COVID-19

0

For discharged patients without suspected or confirmed VTE or other indication for anticoagulation, panel suggests not using anticoagulants

Adding Ipilimumab to Nivolumab No Better in Pretreated Squamous NSCLC

0

No difference in overall survival seen with nivolumab plus ipilimumab, nivolumab alone for advanced, chemotherapy-pretreated disease

No Benefit Seen From Adjuvant Celecoxib in ERBB2-Negative Breast Cancer

0

Disease-free survival did not improve with two years of celecoxib versus placebo in ERBB2-negative breast cancer

CDC Advisers to Discuss Third COVID-19 Vaccine Dose for Immunocompromised

0

Booster shots have become a hot topic since Pfizer-BioNTech said last week it would seek EUA for a third shot of its two-dose vaccine

Ruxolitinib Best for Glucocorticoid-Refractory, -Dependent GVHD

0

Overall response, failure-free survival, symptom response significantly greater with ruxolitinib versus control therapy

Impact of Pandemic Projected for U.S. Breast Cancer Mortality

0

Cumulative increase of 0.52 percent expected in breast cancer deaths by 2030 due to disruptions during the first six months of the pandemic

Five Neutrogena and Aveeno Spray Sunscreens Recalled Due to Benzene

0

Johnson & Johnson said it was still investigating how traces of benzene were discovered in the sunscreens